ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis
15 de Abril de 2014
A total of 191 of 208 patients who received 12 weeks of treatment had a sustained virologic response at post-treatment week 12, for a rate of 91.8% (97.5% CI, 87.6 to 96.1). A total of 165 of 172 patients who received 24 weeks of treatment had a sustained virologic response at post-treatment week 12, for a rate of 95.9% (97.5% CI, 92.6 to 99.3). These rates were superior to the historical control rate. The three mostcommon adverse events were fatigue (in 32.7% of patients in the 12-week group and 46.5% of patients in the 24-week group), headache (in 27.9% and 30.8%, respectively), and nausea (in 17.8% and 20.3%, respectively). The hemoglobin level was less than 10 g per deciliter in 7.2% and 11.0% of patients in the respective groups. Overall, 2.1% of patients discontinued treatment owing to adverse events.
see full study
Relacionados
Sem notícias relacionadas!
CAD em imagens de vídeo 
Segurança Rodoviária 
Álcool e Saúde 
Edições anteriores
Centros informação internacionais 
Ligações com interesse 
CT e Clínicas de Tratamento 
Rede de Referenciação
Eventos
Barcelona dias 21, 22 e 23 de Outubro
28-29 Outubro 2021 auditorio Biblioteca Almeida Garret - PORTO
23-25 de novembro de 2022 Coloque na agenda